South Korean biotechnology company Curocell has strengthened its global expansion strategy by deepening its collaboration with Türkiye’s Biruni Group to commercialize its next-generation CAR-T therapy, Rimqarto (anbal-cabtagene autoleucel). The latest agreement marks a significant milestone for cell therapy, as both organizations move beyond earlier infrastructure planning toward regulatory approval, local manufacturing, and commercial launch preparations for the Turkish market.
The collaboration reflects a broader trend across the global biopharmaceutical industry, where innovative cell and gene therapies are increasingly being localized through regional partnerships instead of relying solely on imports. As countries continue investing in advanced biologics manufacturing capabilities, collaborations between therapy developers and domestic healthcare organizations are becoming central to improving patient access while strengthening national biotechnology ecosystems.
For Türkiye, the partnership aligns with the government’s long-term ambition to establish itself as a regional hub for advanced therapeutics. For Curocell, it represents another step in expanding the international footprint of its CAR-T platform by combining proprietary scientific expertise with strong local manufacturing and regulatory capabilities.
Partnership Strengthens Türkiye’s CAR-T Manufacturing and Regulatory Roadmap
Senior executives from Biruni Group recently visited Curocell’s headquarters to formalize the next phase of their strategic alliance, reaffirming their shared objective of introducing Rimqarto to the Turkish market. The discussions focused on advancing clinical development activities, accelerating regulatory submissions, and preparing commercial infrastructure ahead of the companies’ targeted launch timeline.
The relationship builds upon a consulting agreement established last year, under which Curocell provided technical guidance to support the development of Türkiye’s first commercial CAR-T manufacturing facility. Since then, Biruni Cell Therapy has completed construction of the facility and initiated the process of obtaining Good Manufacturing Practice certification, an essential regulatory requirement before commercial manufacturing operations can begin.
This development represents a meaningful advancement for cell therapy technologies within the country. Instead of depending exclusively on overseas manufacturing, Türkiye is developing domestic production capabilities that could shorten treatment timelines, improve supply chain resilience, and support wider adoption of advanced immunotherapies in the future.
Under the expanded partnership, Biruni Group will oversee funding for local clinical development and regulatory activities, while Curocell will contribute expertise across CAR-T product development, manufacturing processes, quality systems, and technology transfer. This division of responsibilities allows both organizations to leverage their respective strengths while reducing barriers to commercialization.
Executives from both companies indicated that the immediate objective is to secure Turkish regulatory approval for Rimqarto by 2027. If achieved, the therapy would become one of the country’s most advanced locally manufactured CAR-T treatment options, expanding access to personalized immunotherapy for eligible cancer patients.
The collaboration also demonstrates how biotechnology companies are increasingly pursuing regional commercialization strategies that rely on local partnerships rather than establishing entirely independent international operations. Such approaches can simplify regulatory engagement, accelerate market entry, and improve integration with national healthcare systems.
Collaboration Supports Broader Growth of Türkiye’s Biopharmaceutical Ecosystem
Beyond the commercialization of a single therapy, the partnership has wider implications for Türkiye’s biotechnology ambitions. Biruni Group operates an integrated healthcare ecosystem that includes Biruni University, Biruni University Hospital, and Biruni Cell Therapy, providing access to clinical research infrastructure, academic expertise, and specialized patient care.
This combination of research, education, manufacturing, and clinical services creates an environment capable of supporting future development of advanced biologic therapies beyond CAR-T treatments. As demand for personalized medicine continues to grow globally, countries with domestic manufacturing capabilities are expected to play increasingly important roles in regional biopharmaceutical supply chains.
Industry observers note that CAR-T therapy remains one of the fastest-growing areas within oncology, offering highly personalized treatment options by engineering a patient’s immune cells to recognize and eliminate cancer cells. However, widespread adoption has historically been limited by manufacturing complexity, infrastructure requirements, and high production costs. Investments in regional manufacturing facilities therefore represent an important step toward making these therapies more accessible.
Biruni Group’s newly established manufacturing capabilities also complement Türkiye’s national strategy to encourage investment in advanced healthcare technologies and high-value pharmaceutical production. Government support for biotechnology infrastructure has contributed to growing interest from international life sciences companies seeking regional development partners.
Company executives highlighted that combining Biruni’s healthcare network with Curocell’s technological expertise creates opportunities that extend beyond the initial commercialization of Rimqarto. The organizations expect future collaboration across manufacturing, quality management, clinical development, and research initiatives as Türkiye’s cell therapy ecosystem continues to mature.
From Curocell’s perspective, expanding into Türkiye provides access to an emerging healthcare market while demonstrating the scalability of its CAR-T platform beyond its domestic operations. Successfully executing technology transfer, regulatory approval, and commercial manufacturing could strengthen the company’s position for future international expansion into additional markets.
As regulatory preparations continue, both organizations will focus on completing GMP certification, supporting local clinical activities, and engaging with health authorities ahead of the targeted 2027 approval timeline.
The expanded collaboration between Curocell and Biruni Group illustrates how international partnerships are shaping the future of advanced oncology care. By combining proprietary innovation with local manufacturing infrastructure, the companies are laying the foundation for broader adoption of CAR-T therapies while supporting the continued evolution of cell therapy technologies across Türkiye. If the planned commercialization proceeds on schedule, the initiative could become a significant milestone for the country’s biotechnology sector and a model for future regional partnerships in advanced cellular therapies.
Ref; https://www.koreabiomed.com/news/articleViewAmp.html?idxno=32580
